Obesity meta-analysis provides important steer for next-gen drugs
January 8, 2026 / Obesity treatment / Weight regain / Drug adherence / Behavioral weight loss / Obesity drug development
Scientists have created safer mitochondrial-targeting compounds that increase cellular calorie burning without the dangerous side effects of past weight-loss drugs, offering potential for future obesity treatments and improved metabolic health.
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
January 8, 2025 / Obesity treatment / Metabolic disease / GLP-1R agonist / Amylin therapy / Weight loss drugs
Alveus Therapeutics launches with $160M Series A to advance ALV-100 and ALV-200, targeting obesity and metabolic diseases with novel GIPR/GLP-1R and amylin-based therapies aimed at sustained weight loss and improved metabolic outcomes.
Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug
January 6, 2026 / Obesity treatment / AMPK inhibitor / Oral metabolic drug / Eli Lilly partnership / Drug development collaboration
Nimbus and Eli Lilly partner to develop a novel oral obesity drug targeting AMPK, aiming to overcome prior specificity challenges and improve accessibility and cost-effectiveness in metabolic disease treatment.
New BMI uses AI to reveal hidden metabolic disorders
January 7, 2026 / Metabolic BMI / AI in healthcare / Gut microbiome / Obesity research / Metabolic disorders
Researchers developed a metabolic BMI using AI and blood metabolite data to better predict metabolic disease risk—revealing hidden disorders in individuals with normal weight and linking gut microbiota composition to metabolic health outcomes.
Lilly, Nimbus Ink Up-to-$1.3B Oral Obesity Drug Collaboration
January 6, 2026 / Obesity drug development / AMPK activator / Oral weight loss therapy / AI drug discovery / Lilly Nimbus partnership
Eli Lilly and Nimbus Therapeutics expand their partnership to develop an oral small molecule obesity drug targeting AMPK, leveraging AI-driven discovery to address unmet needs in metabolic disease and weight management with a potential $1.3B in milestone payments.
Study Explores Impact of Metformin on Zinc Levels and Metabolic Biomarkers in Obese Children
January 7, 2026 / metformin / pediatric obesity / zinc metabolism / insulin resistance children / metabolic biomarkers
A study found that metformin use in obese children may alter zinc levels and key metabolic biomarkers, indicating broader impacts on nutrient balance and metabolic health beyond its role in managing type 2 diabetes.
Gordian Bio inks obesity research collab with Pfizer
January 8, 2026 / obesity drug discovery / in vivo gene screening / GLP-1 alternatives / Pfizer collaboration obesity / adipocyte metabolic research
Gordian Bio and Pfizer have partnered to identify novel obesity drug targets using an in vivo gene screening platform that evaluates metabolic pathways directly in fat tissue, aiming to develop next-generation treatments beyond GLP-1 therapies.
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
January 6, 2026 / Eli Lilly obesity / Nimbus collaboration drug / oral weight loss therapy / AMPK small molecules / metabolic disease treatment
Eli Lilly has partnered again with Nimbus Therapeutics in a $1.3B deal to develop a preclinical oral obesity drug, expanding its metabolic pipeline and reinforcing its lead in obesity treatment following success with orforglipron and Zepbound.
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
January 8, 2026 / GLP-1 therapy / chronic kidney disease / metabolic hormone treatment / cardiovascular renal protection / obesity diabetes CKD
GLP-1 receptor agonists and next-gen metabolic therapies show promise in treating chronic kidney disease (CKD) by offering cardiovascular and renal protection beyond glucose control, addressing shared pathways of CKD, obesity, and type 2 diabetes.
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
January 8, 2026 / GLP-1 GIP agonist / obesity clinical trial / VK2735 Viking Therapeutics / weight loss maintenance / dual hormone therapy
Viking Therapeutics completed enrollment for a Phase 1 maintenance dosing trial of VK2735, a dual GLP-1/GIP agonist, evaluating long-term weight management strategies in obesity, with both oral and injectable formulations under study for safety and efficacy.
Nimbus, Lilly sign deal to develop new oral obesity drug
January 6, 2026 / AI drug discovery / oral obesity drug / Nimbus Lilly partnership / metabolic disease treatment / weight loss pill
Nimbus Therapeutics and Eli Lilly have partnered to develop AI-driven oral obesity drugs, combining Nimbus’ discovery platform with Lilly’s metabolic disease expertise. The deal includes $55M upfront and up to $1.3B in milestones and royalties.
MASH-Cirrhosis and Obesity: Transforming Care with Shared Medical Appointments
January 6, 2026 / MASH cirrhosis obesity / shared medical appointments / semaglutide safety cirrhosis / sarcopenia liver disease / GLP-1 multidisciplinary care
Cleveland Clinic’s new multidisciplinary shared medical appointment model for MASH cirrhosis and obesity integrates lifestyle support and pharmacotherapy to promote safe weight loss, minimizing sarcopenia risk while addressing liver disease and metabolic dysfunction.
FDA grants breakthrough therapy status to Altimmune’s MASH drug
January 5, 2026 / pemvidutide MASH treatment / GLP-1 liver disease / breakthrough therapy Altimmune / nonalcoholic steatohepatitis drug / fibrosis inflammation obesity
The FDA granted Breakthrough Therapy Designation to Altimmune’s pemvidutide for MASH after Phase 2b data showed significant disease resolution, weight loss, and fibrosis improvement without worsening liver damage, supporting its dual glucagon/GLP-1 receptor mechanism.
Westcove Advises Tampa Bay Medical Research in its Partnership with Alcanza Clinical Research
January 8, 2026 / clinical research partnership / Tampa Bay trials / Alcanza medical collaboration / Martis Capital investment / healthcare M&A advisory
Tampa Bay Medical Research has partnered with Alcanza Clinical Research, expanding clinical trial capabilities through strategic support from Martis Capital, enhancing access to innovative research in therapeutic development.
Metabolic Syndrome in Focus: Emerging Causes, New Diagnostic Approaches and Criteria, and Long-Term Health Consequences
January 7, 2025 / metabolic syndrome risk / obesity cancer link / insulin resistance inflammation / cardiovascular disease obesity / MetS diagnostic criteria
Metabolic syndrome significantly increases the risk of cardiovascular disease and cancer due to shared mechanisms like insulin resistance and inflammation. Emerging diagnostic criteria now emphasize obesity as a central factor, highlighting the importance of early detection and comprehensive management.
Walking, Household Chores Can Be Lifesaving Therapy For People With Metabolic Syndrome
January 7, 2026 / metabolic syndrome exercise / CKM syndrome treatment / light physical activity / walking heart health / household chores longevity
Light daily activities like walking or housework significantly reduce mortality risk in individuals with cardiovascular-kidney-metabolic (CKM) syndrome. A one-hour increase in light activity lowers death risk by up to 20% over 14 years.
From ancient herb to modern medicine: new review unveils the multi-targeted healing potential of Borago officinalis
January 6, 2026 / borage health benefits / Borago officinalis medicine / anti-inflammatory herbs / metabolic syndrome natural treatment / borage clinical research
A new review reveals Borago officinalis (Borage) has multi-targeted therapeutic effects—anti-inflammatory, metabolic, and neuroprotective—driven by bioactive compounds like GLA and quercetin, supporting its potential in treating diabetes, heart disease, and neurodegenerative disorders.
The Impact of Maternal Metabolic Syndrome on Gross Placental Structure in Term Pregnancies: A Comparative Study
January 5, 2026 / maternal metabolic syndrome / placental morphology / pregnancy complications / fetal growth outcomes / placental vascular dysfunction
This study shows maternal metabolic syndrome alters placental and umbilical cord morphology via inflammation, insulin resistance, and vascular dysfunction, potentially impairing fetal growth and influencing neonatal birthweight outcomes in term pregnancies.
Why promising microbiome therapies rarely work in patients
January 8, 2025 / microbiome therapy failure / gut dysbiosis disease / human microbiome research / personalized microbiome medicine / microbiome clinical trials
Microbiome therapies often fail in humans due to biological complexity, ecological resilience, and poor translatability from animal models. Establishing causality remains difficult, though AI, functional profiling, and personalized approaches may improve future clinical outcomes.